Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)

EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator

EUS-guided RFA

Anthony YB Teoh, Professor

Anthony YB Teoh, FRCSEd(Gen)

Anthony YB Teoh

Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic neoplasms.

The aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid pancreatic neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid pancreatic neoplasms.

RFA causes tissue destruction through the application of a high frequency alternating current, generating local temperatures above 60°C and leading to coagulative necrosis. The technique has been widely used in many solid organ tumors and has been shown to result in 5-year survival rates comparable to surgery. The technique is currently the standard therapy in hepatocellular carcinoma and colorectal pulmonary metastasis particular in patients that are not suitable for surgery.

This study is a multi-center prospective study involving four high volume international institutions. Consecutive patients suffering from pancreatic neuroendocrine tumors and pancreatic cancers would be recruited. EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator. The primary outcome would be the overall adverse events rate. Secondary outcomes include mortality, technical success rate, completion ablation rate, 1 \& 3 year overall and disease-free survival.

EUS-guided RFA for Pancreatic Neoplasms

Multi-center Prospective Study on EUS-guided Radiofrequency Ablation for Solid Pancreatic Neoplasms

Adverse events specific to RFA would be graded according to the lexicon of endoscopic adverse events 24. Potential adverse events specific to RFA include: post-RFA syndrome, pancreatitis, pancreatic leak, thermal injury

defined as successful puncture of the lesion with the RFA needle and completion of the ablation cycle.

Number of re-interventions after the procedure

Chinese University of Hong Kong

Associate Professor

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Neoplasm Metastasis

Carcinoma

Carcinoma, Hepatocellular

Lymphoma

Adenocarcinoma

Cholangiocarcinoma

Neuroendocrine Tumors

Pancreatitis

Pancreatitis, Chronic

Autoimmune Pancreatitis

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Chronic Disease

Disease Attributes

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Autoimmune Diseases

Chronic Graft Versus Host Disease

Lymphosarcoma

Bile Duct Cancer

Neuroendocrine Tumor

Neuroepithelioma

Gastrointestinal Agents

All Drugs and Chemicals

Pancrelipase

Pancreatin

Patients with use of AcuCore 22 gauge FNB to collect specimens from GI tract

Using endoscopic ultrasound guided needle to collect biopsies

EchoTip AcuCore

Shelley Farrester

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

EchoTip AcuCore Post-Market Clinical Study

The ability to obtain a sample without failure of the needle system necessitating the use of a new needle to complete the procedure

Cook Research Incorporated

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
EUS-guided RFA for Pancreatic Neoplasms	NCT03218345	Pancreatic Neop...	EUS-guided RFA	18 Years -	Chinese University of Hong Kong
EchoTip AcuCore Post-Market Clinical Study	NCT06358001	Adenocarcinoma Neuroendocrine ... Hepatocellular ... Cholangiocarcin... Malignant Lymph... Metastasis Chronic Pancrea... Autoimmune Panc...	EchoTip AcuCore	18 Years -	Cook Group Incorporated
EchoTip AcuCore Post-Market Clinical Study	NCT06358001	Adenocarcinoma Neuroendocrine ... Hepatocellular ... Cholangiocarcin... Malignant Lymph... Metastasis Chronic Pancrea... Autoimmune Panc...	EchoTip AcuCore	18 Years -	Cook Group Incorporated

Spots Global Cancer Trial Database for interventional eus